Victory Capital Management Inc. Acquires 10,011 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Victory Capital Management Inc. lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 23.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 53,060 shares of the medical instruments supplier's stock after buying an additional 10,011 shares during the quarter. Victory Capital Management Inc. owned about 0.24% of LeMaitre Vascular worth $4,929,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LMAT. Conestoga Capital Advisors LLC increased its stake in shares of LeMaitre Vascular by 1.9% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier's stock worth $183,769,000 after purchasing an additional 36,850 shares during the last quarter. Vanguard Group Inc. increased its position in LeMaitre Vascular by 0.3% during the first quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier's stock worth $103,112,000 after buying an additional 4,964 shares during the last quarter. Copeland Capital Management LLC increased its position in LeMaitre Vascular by 1.0% during the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier's stock worth $108,068,000 after buying an additional 11,318 shares during the last quarter. Congress Asset Management Co. raised its holdings in LeMaitre Vascular by 2.6% during the third quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier's stock valued at $65,888,000 after buying an additional 18,295 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its position in shares of LeMaitre Vascular by 52.2% in the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier's stock worth $21,740,000 after buying an additional 90,573 shares during the last quarter. Institutional investors own 84.64% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on LMAT. Lake Street Capital started coverage on LeMaitre Vascular in a report on Friday, August 2nd. They issued a "buy" rating and a $105.00 target price for the company. Oppenheimer reaffirmed an "outperform" rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. JMP Securities raised their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 20th. Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 price target on the stock. Finally, StockNews.com downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $94.57.

Insiders Place Their Bets

In other news, Director Bridget A. Ross sold 3,750 shares of the business's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 10.79% of the company's stock.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded up $2.10 during trading on Friday, hitting $107.97. 134,445 shares of the stock were exchanged, compared to its average volume of 147,953. The company's fifty day simple moving average is $93.85 and its 200-day simple moving average is $86.84. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of 59.00, a price-to-earnings-growth ratio of 2.59 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1-year low of $51.70 and a 1-year high of $108.09.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. During the same quarter in the previous year, the company earned $0.33 earnings per share. The business's revenue was up 15.6% compared to the same quarter last year. On average, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular's dividend payout ratio is 34.97%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.